Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101254 · ClinicalTrials.gov registry record · Phase 1
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03101254: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT03101254 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03101254, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib
Primary Outcome
DLT is based on CTCAE v4.03. DLT refers to toxicities experienced during the first cycle of treatment that are possibly, probably, or definitely related to the study medication regimen, and grade or category outlined in protocol section 5.4.
Interventions
- DRUG Vemurafenib
- DRUG Cobimetinib
- DRUG LY3022855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2020-11-11 |
| Phase | Phase 1 |
What the finished NCT03101254 record still lists
NCT03101254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Vemurafenib is the first listed.
NCT03101254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03101254 about?
NCT03101254 is a clinical study titled "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma". This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib
What is the current status of trial NCT03101254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-06-06. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT03101254?
The interventions under investigation include: Vemurafenib (DRUG), Cobimetinib (DRUG), LY3022855 (DRUG).
Who is sponsoring clinical trial NCT03101254?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03101254's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI